4.8 Article

Alarmins: awaiting a clinical response

期刊

JOURNAL OF CLINICAL INVESTIGATION
卷 122, 期 8, 页码 2711-2719

出版社

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI62423

关键词

-

资金

  1. Wellcome Trust [096035]
  2. Royal College of Surgeons of England
  3. AO Foundation [F-09-23N]
  4. Novo Nordisk
  5. Merck
  6. Wyeth
  7. GSK

向作者/读者索取更多资源

Alarmins are endogenous molecules that are constitutively available and released upon tissue damage and activate the immune system. Current evidence indicates that uncontrolled and excessive release of alarmins contributes to the dysregulated processes seen in many inflammatory and autoimmune conditions, as well as tumorigenesis and cancer spread. Conversely, alarmins have also been found to play a major role in the orchestration of tissue homeostasis, including repair and remodeling in the heart, skin, and nervous system. Here, we provide an update and overview on alarmins, highlighting the areas that may benefit from this clinical translation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据